EGFR and Thromboembolism: The results of this study showed no difference in the incidence of thromboembolism (ATE or VTE) between VEGF and EGFR inhibitors, and no difference in the time to thromboembolism, suggesting that the risk of thromboembolism is similar between molecular-targeted therapies.